As a result, for greater efficacy and longer-lasting effects, molecular therapeutic approaches are gaining increasing attention in ALS, focusing on inhibiting the toxic gain-of-function (GOF) of ALS-related genes SOD1, C9ORF72, FUS and ATXN2. Here, SOD1 is linked to amyotrophic lateral sclerosis.